Search alternatives:
significant teer » significant gender (Expand Search), significant trend (Expand Search), significant genes (Expand Search)
genes decrease » sizes decrease (Expand Search), greatest decrease (Expand Search), levels decreased (Expand Search)
teer decrease » greater decrease (Expand Search)
significant teer » significant gender (Expand Search), significant trend (Expand Search), significant genes (Expand Search)
genes decrease » sizes decrease (Expand Search), greatest decrease (Expand Search), levels decreased (Expand Search)
teer decrease » greater decrease (Expand Search)
-
1
-
2
-
3
-
4
CKO mice display decreased skin barrier function and perturbed homeostasis.
Published 2025Subjects: -
5
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns = not significant.…”
-
6
-
7
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
8
-
9
ATGL-1 levels increase and lipid droplets decrease in response to <i>N. parisii</i> infection.
Published 2025Subjects: -
10
Loxoprofen and SB225002 administration decreased sound stress exposure-induced hyperalgesia.
Published 2025“…Mice treated with loxoprofen (500 mg/kg) or SB225002 (3 mg/kg) showed significantly decreased response times to the filament compared to Stress + saline group (Stress + loxoprofen (500 mg/kg), 30 min after administration, **<i>P</i> < 0.01, 60 min after administration, ***<i>P</i><i> <i><</i> </i>0.001; Stress + SB225002 (3 mg/kg), 60 min after administration, *<i>P</i> < 0.05). 2-way ANOVA <i>post-hoc</i> Bonferroni test. …”
-
11
-
12
-
13
-
14
-
15
-
16
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
17
-
18
-
19
MiR-129-5p levels were decreased in mouse depression models.
Published 2025“…(n = 3 - 10 mice per group; Data are presented as the mean ± standard error; *, **, ***, and **** indicate significance at p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively.).…”
-
20